Condition: Prostate Cancer · Sponsor: University of California, San Diego
This is a multicenter, multinational trial to evaluate advanced MRI techniques for improved detection of clinically significant prostate cancer (csPCa). The study will enroll 500 participants at 5 clinical centers (100 participants per center). The current standard MRI technique for prostate cancer screening is multiparametric MRI (mpMRI), but two drawbacks include need for intravenous (IV) contrast and dependence on radiologist expertise. The investigators expect that the combination of two other techniques, biparametric MRI (bpMRI) and Restriction Spectrum Imaging restriction score (RSIrs), will help non-expert radiologists achieve similar performance to expert radiologists using bpMRI or mpMRI for detection of csPCa, while avoiding the drawbacks that are present when using mpMRI.
This description comes directly from the study's public registry record.
Tyler Seibert, MD, PhD · 858-246-2180 · tseibert@health.ucsd.edu
Always discuss trial participation with your own doctor first.
| University of California San Diego | San Diego, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Not Yet Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
| Weill Cornell Medical College | New York, New York, United States | Not Yet Recruiting |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge, Cambridgeshire, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06579417